NCT06507852View on ClinicalTrials.gov

A Real-world Study of Inclisiran Adherence, Treatment Patterns, Patient Characteristics, and Effectiveness in ASCVD Patients With Hypercholesterolemia, ASCVD-risk Equivalent Patients With Hypercholesterolemia and Familial Hypercholesterolemia

CompletedOBSERVATIONAL
Enrollment

95

Participants

Timeline

Start Date

October 3, 2022

Primary Completion Date

July 6, 2023

Study Completion Date

July 6, 2023

Conditions
Atherosclerotic Cardiovascular DiseaseHypercholesterolemia
Trial Locations (1)

07936

Novartis, East Hanover

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT06507852 - A Real-world Study of Inclisiran Adherence, Treatment Patterns, Patient Characteristics, and Effectiveness in ASCVD Patients With Hypercholesterolemia, ASCVD-risk Equivalent Patients With Hypercholesterolemia and Familial Hypercholesterolemia | Biotech Hunter | Biotech Hunter